{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T01:03:53Z","timestamp":1780103033148,"version":"3.54.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T00:00:00Z","timestamp":1612396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T00:00:00Z","timestamp":1612396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s12325-020-01583-9","type":"journal-article","created":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T02:03:08Z","timestamp":1612404188000},"page":"1567-1583","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Efficacy of Agomelatine 25\u201350\u00a0mg for the Treatment of Anxious Symptoms and Functional Impairment in Generalized Anxiety Disorder: A Meta-Analysis of Three Placebo-Controlled Studies"],"prefix":"10.1007","volume":"38","author":[{"given":"Dan J.","family":"Stein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon-Paul","family":"Khoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Picarel-Blanchot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Olivier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Van Ameringen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,4]]},"reference":[{"issue":"1","key":"1583_CR1","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/da.20257","volume":"25","author":"DL Hoffman","year":"2008","unstructured":"Hoffman DL, Dukes EM, Wittchen HU. Human and economic burden of generalized anxiety disorder. Depress Anxiety. 2008;25(1):72\u201390.","journal-title":"Depress Anxiety"},{"issue":"9","key":"1583_CR2","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.euroneuro.2011.07.018","volume":"21","author":"HU Wittchen","year":"2011","unstructured":"Wittchen HU, Jacobi F, Rehm J, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011;21(9):655\u201379.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"4","key":"1583_CR3","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1185\/03007995.2013.770731","volume":"29","author":"H Parmentier","year":"2013","unstructured":"Parmentier H, Garcia-Campayo J, Prieto R. Comprehensive review of generalized anxiety disorder in primary care in Europe. Curr Med Res Opin. 2013;29(4):355\u201367.","journal-title":"Curr Med Res Opin"},{"issue":"27\u201328","key":"1583_CR4","first-page":"473","volume":"111","author":"B Bandelow","year":"2014","unstructured":"Bandelow B, Lichte T, Rudolf S, Wiltink J, Beutel ME. The diagnosis of and treatment recommendations for anxiety disorders. Dtsch Arztebl Int. 2014;111(27\u201328):473\u201380.","journal-title":"Dtsch Arztebl Int"},{"issue":"6","key":"1583_CR5","doi-asserted-by":"publisher","first-page":"e100136","DOI":"10.1136\/gpsych-2019-100136","volume":"32","author":"E Bui","year":"2019","unstructured":"Bui E, King F, Melaragno A. Pharmacotherapy of anxiety disorders in the 21st century: a call for novel approaches. Gen Psychiatr. 2019;32(6):e100136.","journal-title":"Gen Psychiatr"},{"key":"1583_CR6","doi-asserted-by":"publisher","first-page":"17024","DOI":"10.1038\/nrdp.2017.24","volume":"3","author":"MG Craske","year":"2017","unstructured":"Craske MG, Stein MB, Eley TC, et al. Anxiety disorders. Nat Rev Dis Primers. 2017;3:17024.","journal-title":"Nat Rev Dis Primers"},{"issue":"11","key":"1583_CR7","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1080\/13543784.2019.1680638","volume":"28","author":"B Schanzer","year":"2019","unstructured":"Schanzer B, Rivas-Grajales AM, Khan A, Mathew SJ. Novel investigational therapeutics for generalized anxiety disorder (GAD). Expert Opin Investig Drugs. 2019;28(11):1003\u201312.","journal-title":"Expert Opin Investig Drugs"},{"issue":"21","key":"1583_CR8","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMcp1502514","volume":"373","author":"MB Stein","year":"2015","unstructured":"Stein MB, Sareen J. Clinical practice. Generalized anxiety disorder. N Engl J Med. 2015;373(21):2059\u201368.","journal-title":"N Engl J Med"},{"issue":"8","key":"1583_CR9","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/nrd3140","volume":"9","author":"C de Bodinat","year":"2010","unstructured":"de Bodinat C, Guardiola-Lemaitre B, Mocaer E, Renard P, Munoz C, Millan MJ. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat Rev Drug Discov. 2010;9(8):628\u201342.","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"1583_CR10","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1124\/jpet.103.051797","volume":"306","author":"MJ Millan","year":"2003","unstructured":"Millan MJ, Gobert A, Lejeune F, et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine(2C) receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther. 2003;306(3):954\u201364.","journal-title":"J Pharmacol Exp Ther"},{"key":"1583_CR11","doi-asserted-by":"publisher","first-page":"3604","DOI":"10.1111\/bph.12720","volume":"171","author":"B Guardiola-Lemaitre","year":"2014","unstructured":"Guardiola-Lemaitre B, Bodinat C, Delagrange P, Millan MJ, Munoz C, Mocaer E. Agomelatine: Mechanism of action and pharmacological profile in relation to antidepressant properties. Br J Pharmacol. 2014;171:3604\u201319.","journal-title":"Br J Pharmacol"},{"issue":"4","key":"1583_CR12","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1007\/s00213-004-1962-z","volume":"177","author":"MJ Millan","year":"2005","unstructured":"Millan MJ, Brocco M, Gobert A, Dekeyne A. Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade. Psychopharmacology. 2005;177(4):448\u201358.","journal-title":"Psychopharmacology"},{"key":"1583_CR13","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.2147\/NDT.S67470","volume":"11","author":"MN Levitan","year":"2015","unstructured":"Levitan MN, Papelbaum M, Nardi AE. Profile of agomelatine and its potential in the treatment of generalized anxiety disorder. Neuropsychiatr Dis Treat. 2015;11:1149\u201355.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"5","key":"1583_CR14","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/JCP.0b013e318184ff5b","volume":"28","author":"DJ Stein","year":"2008","unstructured":"Stein DJ, Ahokas AA, de Bodinat C. Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2008;28(5):561\u20136.","journal-title":"J Clin Psychopharmacol"},{"issue":"7","key":"1583_CR15","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.4088\/JCP.11m07493","volume":"73","author":"DJ Stein","year":"2012","unstructured":"Stein DJ, Ahokas AA, Albarran Severo C, Olivier V, Allgulander C. Agomelatine prevents relapse in generalised anxiety disorder: a 6-month placebo-controlled discontinuation study. J Clin Psychiatry. 2012;73(7):1002\u20138.","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"1583_CR16","doi-asserted-by":"publisher","first-page":"362","DOI":"10.4088\/JCP.13m08433","volume":"75","author":"DJ Stein","year":"2014","unstructured":"Stein DJ, Ahokas A, Marquez MS, et al. Agomelatine in generalized anxiety disorder: an active comparator and placebo-controlled study. J Clin Psychiatry. 2014;75(4):362\u20138.","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"1583_CR17","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.euroneuro.2017.02.007","volume":"27","author":"DJ Stein","year":"2017","unstructured":"Stein DJ, Ahokas A, Jarema M, et al. Efficacy and safety of agomelatine (10 or 25 mg\/day) in non-depressed out-patients with generalized anxiety disorder: a 12-week, double-blind, placebo-controlled study. Eur Neuropsychopharmacol. 2017;27(5):526\u201337.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"8","key":"1583_CR18","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.euroneuro.2018.05.006","volume":"28","author":"DJ Stein","year":"2018","unstructured":"Stein DJ, Khoo JP, Ahokas A, et al. 12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25\u201350mg\/day) versus escitalopram (10\u201320mg\/day) in out-patients with severe generalized anxiety disorder. Eur Neuropsychopharmacol. 2018;28(8):970\u20139.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"10173","key":"1583_CR19","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/S0140-6736(18)31793-8","volume":"393","author":"A Slee","year":"2019","unstructured":"Slee A, Nazareth I, Bondaronek P, Liu Y, Cheng Z, Freemantle N. Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis. Lancet. 2019;393(10173):768\u201377.","journal-title":"Lancet"},{"issue":"1","key":"1583_CR20","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s40263-014-0217-8","volume":"29","author":"H Wilson","year":"2015","unstructured":"Wilson H, Mannix S, Oko-osi H, Revicki DA. The impact of medication on health-related quality of life in patients with generalized anxiety disorder. CNS Drugs. 2015;29(1):29\u201340.","journal-title":"CNS Drugs"},{"issue":"Suppl 3","key":"1583_CR21","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/00004850-199606003-00015","volume":"11","author":"DV Sheehan","year":"1996","unstructured":"Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol. 1996;11(Suppl 3):89\u201395.","journal-title":"Int Clin Psychopharmacol"},{"key":"1583_CR22","first-page":"CD008851","volume":"12","author":"G Guaiana","year":"2013","unstructured":"Guaiana G, Gupta S, Chiodo D, Davies SJ, Haederle K, Koesters M. Agomelatine versus other antidepressive agents for major depression. Cochrane Database Syst Rev. 2013;12:CD008851.","journal-title":"Cochrane Database Syst Rev"},{"key":"1583_CR23","first-page":"122","volume":"238","author":"SH Kennedy","year":"2018","unstructured":"Kennedy SH, Grouin JM, Cadour S, Robert V, Picarel-Blanchot F. Relative short-term efficacy and acceptability of agomelatine versus vortioxetine in adult patients suffering from major depressive disorder. Hum Psychopharmacol. 2018;238:122\u20138.","journal-title":"Hum Psychopharmacol"},{"key":"1583_CR24","doi-asserted-by":"publisher","first-page":"g1888","DOI":"10.1136\/bmj.g1888","volume":"348","author":"D Taylor","year":"2014","unstructured":"Taylor D, Sparshatt A, Varma S, Olofinjana O. Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies. BMJ. 2014;348:g1888.","journal-title":"BMJ"},{"issue":"1","key":"1583_CR25","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/YIC.0000000000000147","volume":"32","author":"MB Generoso","year":"2017","unstructured":"Generoso MB, Trevizol AP, Kasper S, Cho HJ, Cordeiro Q, Shiozawa P. Pregabalin for generalized anxiety disorder: an updated systematic review and meta-analysis. Int Clin Psychopharmacol. 2017;32(1):49\u201355.","journal-title":"Int Clin Psychopharmacol"},{"issue":"8","key":"1583_CR26","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1080\/14656566.2018.1472767","volume":"19","author":"AF Gomez","year":"2018","unstructured":"Gomez AF, Barthel AL, Hofmann SG. Comparing the efficacy of benzodiazepines and serotonergic anti-depressants for adults with generalized anxiety disorder: a meta-analytic review. Expert Opin Pharmacother. 2018;19(8):883\u201394.","journal-title":"Expert Opin Pharmacother"},{"issue":"10","key":"1583_CR27","doi-asserted-by":"publisher","first-page":"e0185865","DOI":"10.1371\/journal.pone.0185865","volume":"12","author":"X Li","year":"2017","unstructured":"Li X, Zhu L, Su Y, Fang S. Short-term efficacy and tolerability of venlafaxine extended release in adults with generalized anxiety disorder without depression: a meta-analysis. PLoS ONE. 2017;12(10):e0185865.","journal-title":"PLoS ONE"},{"issue":"3","key":"1583_CR28","doi-asserted-by":"publisher","first-page":"e0194501","DOI":"10.1371\/journal.pone.0194501","volume":"13","author":"X Li","year":"2018","unstructured":"Li X, Zhu L, Zhou C, et al. Efficacy and tolerability of short-term duloxetine treatment in adults with generalized anxiety disorder: a meta-analysis. PLoS ONE. 2018;13(3):e0194501.","journal-title":"PLoS ONE"},{"key":"1583_CR29","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ajp.2017.01.016","volume":"26","author":"N Zareifopoulos","year":"2017","unstructured":"Zareifopoulos N, Dylja I. Efficacy and tolerability of vilazodone for the acute treatment of generalized anxiety disorder: A meta-analysis. Asian J Psychiatr. 2017;26:115\u201322.","journal-title":"Asian J Psychiatr"},{"issue":"6","key":"1583_CR30","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1517\/13543784.2014.911840","volume":"23","author":"K Demyttenaere","year":"2014","unstructured":"Demyttenaere K. Agomelatine in treating generalized anxiety disorder. Expert Opin Investig Drugs. 2014;23(6):857\u201364.","journal-title":"Expert Opin Investig Drugs"},{"key":"1583_CR31","volume-title":"Diagnostic and Statistical Manual of Mental Disorders, 4th Edn (DSM-IV-TR)","author":"American Psychiatric Association","year":"2000","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th Edn (DSM-IV-TR). 4th ed. Washington DC: American Psychiatric Association; 2000.","edition":"4"},{"issue":"1","key":"1583_CR32","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","volume":"32","author":"M Hamilton","year":"1959","unstructured":"Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50\u20135.","journal-title":"Br J Med Psychol"},{"issue":"2","key":"1583_CR33","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1097\/YIC.0b013e3282f2b4d6","volume":"23","author":"KH Sheehan","year":"2008","unstructured":"Sheehan KH, Sheehan DV. Assessing treatment effects in clinical trials with the discan metric of the Sheehan Disability Scale. Int Clin Psychopharmacol. 2008;23(2):70\u201383.","journal-title":"Int Clin Psychopharmacol"},{"issue":"6","key":"1583_CR34","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","volume":"67","author":"AS Zigmond","year":"1983","unstructured":"Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361\u201370.","journal-title":"Acta Psychiatr Scand"},{"key":"1583_CR35","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1192\/bjp.134.4.382","volume":"134","author":"SA Montgomery","year":"1979","unstructured":"Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382\u20139.","journal-title":"Br J Psychiatry"},{"issue":"2\u20133","key":"1583_CR36","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jad.2004.11.011","volume":"87","author":"WK Goodman","year":"2005","unstructured":"Goodman WK, Bose A, Wang Q. Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials. J Affect Disord. 2005;87(2\u20133):161\u20137.","journal-title":"J Affect Disord"},{"issue":"2","key":"1583_CR37","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/da.10141","volume":"19","author":"P Meoni","year":"2004","unstructured":"Meoni P, Hackett D, Lader M. Pooled analysis of venlafaxine XR efficacy on somatic and psychic symptoms of anxiety in patients with generalized anxiety disorder. Depress Anxiety. 2004;19(2):127\u201332.","journal-title":"Depress Anxiety"},{"key":"1583_CR38","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jpsychires.2015.02.017","volume":"64","author":"CU Pae","year":"2015","unstructured":"Pae CU, Wang SM, Han C, et al. Vortioxetine, a multimodal antidepressant for generalized anxiety disorder: a systematic review and meta-analysis. J Psychiatr Res. 2015;64:88\u201398.","journal-title":"J Psychiatr Res"},{"issue":"7","key":"1583_CR39","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1017\/S0033291705004538","volume":"35","author":"RC Kessler","year":"2005","unstructured":"Kessler RC, Brandenburg N, Lane M, et al. Rethinking the duration requirement for generalized anxiety disorder: evidence from the National Comorbidity Survey Replication. Psychol Med. 2005;35(7):1073\u201382.","journal-title":"Psychol Med"},{"issue":"4","key":"1583_CR40","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.jbtep.2007.10.010","volume":"39","author":"PJ Norton","year":"2008","unstructured":"Norton PJ, Temple SR, Pettit JW. Suicidal ideation and anxiety disorders: elevated risk or artifact of comorbid depression? J Behav Ther Exp Psychiatry. 2008;39(4):515\u201325.","journal-title":"J Behav Ther Exp Psychiatry"},{"issue":"4","key":"1583_CR41","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/mpr.323","volume":"19","author":"LS Matza","year":"2010","unstructured":"Matza LS, Morlock R, Sexton C, Malley K, Feltner D. Identifying HAM-A cutoffs for mild, moderate, and severe generalized anxiety disorder. Int J Methods Psychiatr Res. 2010;19(4):223\u201332.","journal-title":"Int J Methods Psychiatr Res"},{"issue":"7","key":"1583_CR42","doi-asserted-by":"publisher","first-page":"785","DOI":"10.4088\/JCP.v64n0708","volume":"64","author":"MR Liebowitz","year":"2003","unstructured":"Liebowitz MR, DeMartinis NA, Weihs K, et al. Efficacy of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled study. J Clin Psychiatry. 2003;64(7):785\u201392.","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"1583_CR43","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1176\/appi.ajp.163.1.148","volume":"163","author":"M Zimmerman","year":"2006","unstructured":"Zimmerman M, McGlinchey JB, Posternak MA, Friedman M, Attiullah N, Boerescu D. How should remission from depression be defined? The depressed patient\u2019s perspective. Am J Psychiatry. 2006;163(1):148\u201350.","journal-title":"Am J Psychiatry"},{"issue":"2","key":"1583_CR44","first-page":"81","volume":"21","author":"DJ Stein","year":"2009","unstructured":"Stein DJ, Bandelow B, Dolberg OT, Andersen HF, Baldwin DS. Anxiety symptom severity and functional recovery or relapse. Ann Clin Psychiatry. 2009;21(2):81\u20138.","journal-title":"Ann Clin Psychiatry"},{"issue":"1","key":"1583_CR45","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/mpr.358","volume":"21","author":"MJ Gameroff","year":"2012","unstructured":"Gameroff MJ, Wickramaratne P, Weissman MM. Testing the Short and Screener versions of the Social Adjustment Scale-Self-report (SAS-SR). Int J Methods Psychiatr Res. 2012;21(1):52\u201365.","journal-title":"Int J Methods Psychiatr Res"},{"issue":"Suppl 1","key":"1583_CR46","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1016\/S0924-977X(97)00420-3","volume":"7","author":"M Bosc","year":"1997","unstructured":"Bosc M, Dubini A, Polin V. Development and validation of a social functioning scale, the Social Adaptation Self-evaluation Scale. Eur Neuropsychopharmacol. 1997;7(Suppl 1):S57\u201370.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"6","key":"1583_CR47","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","volume":"30","author":"JE Ware Jr","year":"1992","unstructured":"Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473\u201383.","journal-title":"Med Care"},{"issue":"4","key":"1583_CR48","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2165\/00023210-200519040-00004","volume":"19","author":"P Bech","year":"2005","unstructured":"Bech P. Social functioning: should it become an endpoint in trials of antidepressants? CNS Drugs. 2005;19(4):313\u201324.","journal-title":"CNS Drugs"},{"issue":"6","key":"1583_CR49","doi-asserted-by":"publisher","first-page":"587","DOI":"10.4088\/JCP.12m08250","volume":"74","author":"R Heun","year":"2013","unstructured":"Heun R, Ahokas A, Boyer P, Gim\u00e9nez-Montesinos N, Pontes-Soares F, Olivier V. The efficacy of agomelatine in elderly patients with major recurrent depressive disorder: a placebo controlled study. J Clin Psychiatry. 2013;74(6):587\u201394.","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"1583_CR50","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.euroneuro.2014.01.006","volume":"24","author":"SH Kennedy","year":"2014","unstructured":"Kennedy SH, Avedisova A, Gimenez-Montesinos N, Belaidi C, de Bodinat C. A placebo-controlled study of three agomelatine dose regimens (10mg, 25mg, 25\u201350mg) in patients with major depressive disorder. Eur Neuropsychopharmacol. 2014;24(4):553\u201363.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"2","key":"1583_CR51","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.euroneuro.2015.09.006","volume":"26","author":"SH Kennedy","year":"2016","unstructured":"Kennedy SH, Avedisova A, Belaidi C, Picarel-Blanchot F, de Bodinat C. Sustained efficacy of agomelatine 10 mg, 25 mg, and 25\u201350 mg on depressive symptoms and functional outcomes in patients with major depressive disorder. A placebo-controlled study over 6 months. Eur Neuropsychopharmacol. 2016;26(2):378\u201389.","journal-title":"Eur Neuropsychopharmacol"},{"key":"1583_CR52","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.jad.2016.03.048","volume":"199","author":"T Udristoiu","year":"2016","unstructured":"Udristoiu T, Dehelean P, Nuss P, Raba V, Picarel-Blanchot F, de Bodinat C. Early effect on general interest, and short-term antidepressant efficacy and safety of agomelatine (25\u201350mg\/day) and escitalopram (10\u201320mg\/day) in outpatients with Major Depressive Disorder. A 12-week randomised double-blind comparative study. J Affect Disord. 2016;199:6\u201312.","journal-title":"J Affect Disord"},{"issue":"7","key":"1583_CR53","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1002\/da.21937","volume":"29","author":"N Hoertel","year":"2012","unstructured":"Hoertel N, Le SY, Blanco C, Lavaud P, Dubertret C. Generalizability of clinical trial results for generalized anxiety disorder to community samples. Depress Anxiety. 2012;29(7):614\u201320.","journal-title":"Depress Anxiety"},{"issue":"4","key":"1583_CR54","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s40263-019-00611-9","volume":"33","author":"M Pladevall-Vila","year":"2019","unstructured":"Pladevall-Vila M, Pottegard A, Schink T, et al. Risk of acute liver injury in agomelatine and other antidepressant users in four European countries: a cohort and nested case-control study using automated health data sources. CNS Drugs. 2019;33(4):383\u201395.","journal-title":"CNS Drugs"},{"issue":"4","key":"1583_CR55","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1176\/appi.ajp.2013.13050709","volume":"171","author":"CS Voican","year":"2014","unstructured":"Voican CS, Corruble E, Naveau S, Perlemuter G. Antidepressant-induced liver injury: a review for clinicians. Am J Psychiatry. 2014;171(4):404\u201315.","journal-title":"Am J Psychiatry"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01583-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-020-01583-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01583-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T14:05:48Z","timestamp":1614866748000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-020-01583-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,4]]},"references-count":55,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["1583"],"URL":"https:\/\/doi.org\/10.1007\/s12325-020-01583-9","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,4]]},"assertion":[{"value":"14 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}